Providence immunotherapy research presented at global conference
Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, joined leading cancer immunotherapy professionals around the world for the largest cancer immunotherapy conference, the 36th annual meeting of the Society for Immunotherapy of Cancer (SITC21).
Our team of internationally recognized experts were featured in education programs and contributed to 14 abstracts selected for presentation at this year’s conference.
Of note, Bernard A. Fox, Ph.D., member, and Harder Family Endowed Chair for Cancer Research, Molecular and Tumor Immunology Laboratory, and Andrew D. Weinberg, Ph.D., member, and Judith Ann Hartmann Endowed Chair, Basic Immunology Laboratory, participated in two preconference symposiums.
Dr. Fox served as a program co-organizer of the World Immunotherapy Council's 4th Young Investigator Symposium. This program brings together young scientists and future leaders to highlight worldwide initiatives in cancer immunotherapy and facilitate scientific exchange and networking.
Dr. Weinberg led a panel discussion on "Myths vs. Knowledge on Clinical Therapeutic Mechanisms - Lessons Learned" as part of the Immuno-Resistance and Sequencing Symposium. He shared with attendees how OX40 agonists can increase tumor-reactive T cells in a tumor and lead to improved survival outcomes for patients.
View all of our abstracts with links to further reading:
Abstract 583: Exploring the Potential of T Cell Acute Lymphoblastic Leukemia (T-ALL) for Generating Leukemia-Specific T cell Responses that can be Therapeutically Harnessed with Immunotherapy. Triplett, Rios...Weinberg.
Abstract 601: Sequencing Immunotherapy Before Lymphatic Ablation Unleashes cDC1-Dependent Antitumor Immunity in HNSCC. Saddawi-Konefka...Fox et al.
Biomarkers, Immune Monitoring and Novel Technologies
Abstract 85: Detection of human angiotensin-converting enzyme 2 receptor on human cancer cell lines. Moudgil…Fox et al.
Abstract 94: Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer. Chun…Nikitin…Koguchi, Redmond, Bernard, Rajamanickam…Conrad…Urba…Conlin…Page.
Clinical Trials Completed
Abstract 354: Lenvatinib and pembrolizumab in advanced endometrial carcinoma: long-term efficacy and safety update from a phase 1b/2 study. Makker…Taylor.
Abstract 381: Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: The phase 1b MITCI study. Curti et al.
Abstract 383: Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody. Fernandez-Penas…Ballesteros-Merino, Jensen, Fox at al.
Clinical Trials in Progress
Abstract 398: neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer. Sanchez, Conlin…Stanton…Sun, Redmond, Page.
Abstract 399: A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer. Page…Chun, Sun, Koguchi, Redmond…Urba et al.
Abstract 474: Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress). Davar…Sanborn et al.
Abstract 509: A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer. Naing…Bifulco et al.
Abstract 523: Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors. Shum…Leidner et al.
Abstract 596: MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination. Rolig, Rose…Redmond.
Abstract 165: Generating enhanced tumor infiltrating lymphocytes through microfluidic cell squeezing. Bridgen...Thalhofer, Montler, Weinberg et al.
About Earle A. Chiles Research Institute:
The Earle A. Chiles Research Institute is a world-class research facility dedicated to discovering curative therapies for cancer patients. Our main area of investigation is cancer immunotherapy, a specialized field of study focused on harnessing the innate power of the immune system to cure cancer.